Silvia Sommariva1, Benedetta Pongiglione2, Rosanna Tarricone3. 1. Centre for Research on Health and Social Care Management (CERGAS), Milan, Italy. Electronic address: silvia.sommariva@unibocconi.it. 2. Department of Medical Statistics, Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK. 3. Centre for Research on Health and Social Care Management (CERGAS), Milan, Italy; Department of Policy Analysis and Public Management, University Bocconi, Milan, Italy.
Abstract
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a particularly distressing event for oncology patients. This review aims at analyzing the impact of CINV on Health-Related Quality of Life (QoL) and on the use of healthcare resources. METHODS: A systematic search was conducted according to the PRISMA statement on MEDLINE, EMBASE and NHS EED. RESULTS: Sixty-seven studies were included in the final selection. Despite the availability of numerous treatment options, CINV was found to have a strong impact on HRQoL of patients. Direct costs are particularly affected, but this result could be due to scarcity of studies assessing indirect costs. CONCLUSIONS: Evidence supports the notion that CINV continues to have a negative impact on HRQoL of patients, even for those receiving moderately emetic chemotherapy. Further studies need also to collect data on the cost of CINV, particularly indirect costs, to ensure that decisions on use of healthcare resources are better supported.
BACKGROUND: Chemotherapy-induced nausea and vomiting (CINV) is a particularly distressing event for oncology patients. This review aims at analyzing the impact of CINV on Health-Related Quality of Life (QoL) and on the use of healthcare resources. METHODS: A systematic search was conducted according to the PRISMA statement on MEDLINE, EMBASE and NHS EED. RESULTS: Sixty-seven studies were included in the final selection. Despite the availability of numerous treatment options, CINV was found to have a strong impact on HRQoL of patients. Direct costs are particularly affected, but this result could be due to scarcity of studies assessing indirect costs. CONCLUSIONS: Evidence supports the notion that CINV continues to have a negative impact on HRQoL of patients, even for those receiving moderately emetic chemotherapy. Further studies need also to collect data on the cost of CINV, particularly indirect costs, to ensure that decisions on use of healthcare resources are better supported.
Authors: S Carnio; D Galetta; V Scotti; D L Cortinovis; A Antonuzzo; S Pisconti; A Rossi; O Martelli; F L Cecere; A Lunghi; A Del Conte; E S Montagna; J Topulli; D Pelizzoni; S G Rapetti; M Gianetta; M V Pacchiana; V Pegoraro; N Cataldo; E Bria; S Novello Journal: Support Care Cancer Date: 2017-12-21 Impact factor: 3.603
Authors: Joseph S Bubalo; Jon D Herrington; Marc Takemoto; Patricia Willman; Michael S Edwards; Casey Williams; Alan Fisher; Alison Palumbo; Eric Chen; Charles Blanke; Charles D Lopez Journal: Support Care Cancer Date: 2017-10-31 Impact factor: 3.603
Authors: L Lee Dupuis; Kara M Kelly; Jeffrey P Krischer; Anne-Marie Langevin; Roy N Tamura; Ping Xu; Lu Chen; E Anders Kolb; Nicole J Ullrich; Olle Jane Z Sahler; Eleanor Hendershot; Ann Stratton; Lillian Sung; Thomas W McLean Journal: Cancer Date: 2017-12-19 Impact factor: 6.860
Authors: Nirosha Mahendraratnam; Joel F Farley; Ethan Basch; Amber Proctor; Stephanie B Wheeler; Stacie B Dusetzina Journal: Support Care Cancer Date: 2019-03-26 Impact factor: 3.603
Authors: Sylvia L Crowder; Aasha I Hoogland; Taylor L Welniak; Elizabeth A LaFranchise; Kristen M Carpenter; Daneng Li; Daniel M Rotroff; Arshiya Mariam; Christine M Pierce; Stacy M Fischer; Anita Y Kinney; Thi Dong-Binh Tran; Farzaneh Rastegari; Donna L Berry; Martine Extermann; Richard D Kim; Danielle B Tometich; Jane C Figueiredo; Jameel Muzaffar; Shahla Bari; Kea Turner; George M Weinstock; Heather S L Jim Journal: Cancer Date: 2021-10-13 Impact factor: 6.860